Trial
NCT02322814
A Study of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as Initial Treatment for Participants With Triple-Negative Breast Cancer That Has Spread
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Hoffmann-La Roche
Collaborators
—
Condition
Breast Cancer
Intervention
Cobimetinib
Why stopped
Sponsor's decision
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-04-13